/
RSS Feed
CHICAGO—Findings from a Phase III trial show that initial single-agent therapy with a new oral drug called afatinib prolongs progression- free survival in patients with advanced lung adenocarcinomas that harbour EGFR mutations, compared with current standard treatment. Afatinib broadly blocks the ErbB family receptors associated with the EGFR pathway; patients with two specific types of EGFR mutations experienced the greatest treatment benefit. James Yang MD, PhD of the National Taiwan University Hospital in Taipei discussed the findings with Peter Goodwin.
LISTEN
[audio:https://www.audiomedica.com/podcasting/news/120611JamesYangINTERVIEWLoRes.mp3]
